Date Mailed: December 13, 2006

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 12152.118USW1	Application Number: 10/779,399
	Applicant: Uckun et al.	
	Filing Date: 2/13/2004	Group Art Unit: 1645

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
NN	6,294,575	9/25/01	Uckun			
NN	6,303,652 10	8/16/01	Uckun			

MCB 3-14-07

FOREIGN PATENT DOCUMENTS

	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

NN		Baraldi et al., 1999, *Structure*, Vol. 7, No. 4, pp. 449-460 Structure of the PH Domain from Bruton's Tyrosine Kinase in Complexe with Inositol 1,3,4,5-tetrakisphosphate
NN		Cozier et al., 2000, *Biochem J.*, 349, 333-342 Molecular Modelling and Site-directed Mutagenesis of the Inositol 1,3,4,5-tetrakisphosphate-binding Pleckstrin Homology Domain from teh Ras GTPase-activating Protein GAP1^{IP4BP}
NN		Mahajan et al., *J. Biol Chem*, 1999, Vol. 274, No. 14, pp. 9587-09599 Rational Design and Synthesis of a Novel Anti-leukemic Agent Targeting Bruton's Tyrosine Kinase (BTK), LFM-A13 [α-Cyano-β-Hydroxy-β-Methyl-*N*-(2,5-Dibromophenyl)Propenamide]
NN		Ghosh et al., 1999, *Acta Cryst*, C55, 1364-1365 α-Cyano-*N*-(2,5-dibromophenyl)-β-Hydroxybut-2-enamide

EXAMINER	/Nashaat Nashed/ (12/19/2006)	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.

*Substitute Disclosure Statement Form (PTO-1449)